The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Dysfunctional HDL and atherosclerotic cardiovascular disease
Open accessAbstract
High-density lipoproteins (HDLs) protect against atherosclerosis by removing excess cholesterol from macrophages through the ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1) pathways involved in reverse cholesterol transport. Factors that impair the availability of functional apolipoproteins or the activities of ABCA1 and ABCG1 could, therefore, strongly influence atherogenesis. HDL also inhibits lipid oxidation, restores endothelial function, exerts anti-inflammatory and antiapoptotic actions, and exerts anti-inflammatory actions in animal models. Such properties could contribute considerably to the capacity of HDL to inhibit atherosclerosis. Systemic and vascular inflammation has been proposed to convert HDL to a dysfunctional form that has impaired antiatherogenic effects. A loss of anti-inflammatory and antioxidative proteins, perhaps in combination with a gain of proinflammatory proteins, might be another important component in rendering HDL dysfunctional. The proinflammatory enzyme myeloperoxidase induces both oxidative modification and nitrosylation of specific residues on plasma and arterial apolipoprotein A-I to render HDL dysfunctional, which results in impaired ABCA1 macrophage transport, the activation of inflammatory pathways, and an increased risk of coronary artery disease. Understanding the features of dysfunctional HDL or apolipoprotein A-I in clinical practice might lead to new diagnostic and therapeutic approaches to atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies have indicated a complete loss of function and dysfunction gain concerning anti-inflammatory, vasodilatory, and antiapoptotic activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, there are instances where HDL’s ability to deliver cholesterol esters via SCARB1 may be reduced, indicating only a partial loss of function.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“It was noted that HDL could lose its anti-inflammatory properties and even develop proinflammatory characteristics.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, when it comes to antioxidative activity and cholesterol efflux capacity, the deficiency observed in HDL’s normal function falls short of complete dysfunction [9].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequent research has shown that the extent of HDL’s normal function loss and dysfunction gain can vary depending on its different biological activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Dysfunctional HDL (dys-HDL) are HDL cholesterol particles with high pro-atherogenic characteristics, characterized by the loss of typical antioxidant properties, becoming carriers of oxidized lipids themselves.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
In the citing paper
“Moreover, modulations in HDL particle composition can transform it to dysfunctional and, through this modulation, increase the risk of CVD40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
In the citing paper
“Decrease in HDL has been regarded as one important risk factor for cardiovascular diseases40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Large-scale association analysis identifies new risk loci for coronary artery disease
The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2480 · Cited by 1,614
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390
Daugherty, A., Dunn, J. L., Rateri, D. L., & Heinecke, J. W. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117342 · Cited by 1,269
Self-citation
Cited by
Sorted by citations
Items 401–500 of 821
Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1
Hooshdaran, B., Pressly, B. B., Alferiev, I. S., Smith, J. D., Zoltick, P. W., Tschabrunn, C. M., Wilensky, R. L., Gorman, R. C., Levy, R. J., & Fishbein, I. (2022) · Scientific Reports · doi:10.1038/s41598-022-09524-y · Cited by 11
Dod, R., Rajendran, A., Kathrotia, M., Clarke, A., & Dodani, S. (2022) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-022-01306-6 · Cited by 10
Yang, Z., Liang, X., & Yang, L. (2022) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-022-01799-2 · Cited by 10
Sodhi, K., & Bracero, L. A. (2016) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000393 · Cited by 10
Androulakis, E. S., Zacharia, E. M., Παπαγεωργίου, Ν., Lioudaki, E., Bertsias, D., Charakida, M., Siasos, G., & Tousoulis, D. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170209145622 · Cited by 10
Gagliano‐Jucá, T., Burak, M. F., Pencina, K. M., Li, Z., Edwards, R. R., Travison, T. G., & Basaria, S. S. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01068 · Cited by 11
Fibrillar conformation of an apolipoprotein A-I variant involved in amyloidosis and atherosclerosis
Gisonno, R. A., Prieto, E. D., Gorgojo, J. P., Curto, L. M., Rodrı́guez, M. E., Rosu, S. A., Gaddi, G. M., Finarelli, G. S., Cortez, M. F., Schinella, G. R., et al. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129515 · Cited by 10
A potential association of meditation with menopausal symptoms and blood chemistry in healthy women
Sung, M.-K., Lee, U. S., Ha, N. H., Koh, E., & Yang, H. (2020) · Medicine · doi:10.1097/md.0000000000022048 · Cited by 10
Okada, T., Sumida, M., Ohama, T., Katayama, Y., Saga, A., Inui, H., Kanno, K., Masuda, D., Koseki, M., Nishida, M., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.56887 · Cited by 10
Karpouzas, G. A., Papotti, B., Ormseth, S. R., Palumbo, M., Hernández, E., Adorni, M. P., Zimetti, F., Budoff, M. J., & Ronda, N. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103029 · Cited by 10
Takaeko, Y., Matsui, S., Kajikawa, M., Maruhashi, T., Yamaji, T., Harada, T., Han, Y., Hashimoto, H., Kihara, Y., Hida, E., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038121 · Cited by 10
Lee, G., Kang, K., Yun, H. H., Jo, W., & Oh, T. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13597 · Cited by 12
He, C., Liu, Y., Dai, Y., Yao, Y., Li, M., Xie, J., Wang, Y., Qu, X., & Deng, Y. (2023) · Italian Journal of Animal Science · doi:10.1080/1828051x.2023.2271921 · Cited by 9
High-density lipoproteins. Part 2. Impact of disease states on functionality
Gluba-Brzózka, A., Olszewski, R., Franczyk, B., Młynarska, E., Rysz-Górzyńska, M., Rysz, J., Surma, S., Sheth, S., Banach, M., & Toth, P. P. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101073 · Cited by 12
Huang, X., Li, G., Xu, B., Zhang, J., Wang, X., Cheng, X., Jayachandran, M., Huang, Y., & Qu, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.633856 · Cited by 9
Siurana, J. M., Sabaté-Rotés, A., Amigó, N., Martínez-Micaelo, N., Arciniegas, L., Riaza, L., Mogas, E., Rosés‐Noguer, F., Ventura, P. S., & Yeste, D. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.887771 · Cited by 9
SREBPs as the potential target for solving the polypharmacy dilemma
Wang, X., Chen, Y., Meng, H., & Meng, F. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2023.1272540 · Cited by 11
Chronic kidney disease and coronary atherosclerosis: evidences from intravascular imaging
Iwai, T., Kataoka, Y., Otsuka, F., Asaumi, Y., Nicholls, S. J., Noguchi, T., & Yasuda, S. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1676150 · Cited by 10
Abudukeremu, A., Huang, C., Li, H., Sun, R., Liu, X., Wu, X., Xie, X., Huang, J., Zhang, J., Bao, J., et al. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.700233 · Cited by 9
High‐density lipoprotein lipid peroxidation as a diagnostics biomarker in coronary artery disease
Yazdandoust, S., Parizadeh, S. M. R., Ghayour‐Mobarhan, M., Yaghmaei, P., & Sahebkar, A. H. (2022) · BioFactors · doi:10.1002/biof.1819 · Cited by 9
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies
Yvan‐Charvet, L., & Cariou, B. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000505 · Cited by 10
The impact of myeloperoxidase on HDL function in myocardial infarction
Tietge, U. J. F. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000394 · Cited by 9
Tokgözoğlu, L. S., & Zamorano, J. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-4-4 · Cited by 11
A new perspective on the current and future development potential of ABCG1
Zeng, G.-G., Lei, Q., Jiang, W., Zhang, X., Nie, L.-L., Gong, X., & Zheng, K. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.102161 · Cited by 8
Luo, W., Tao, Z., Li, X., Xu, Y. X. Z., Yang, C., Sun, R., Wang, M., Ji, Z., & Ma, G. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1604284 · Cited by 9
Unraveling the metabolic pathways between atherosclerosis and sarcopenia
Yu, M., Ge, L., Fu, C., & Zhao, R. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1762825 · Cited by 9
Effects of superoxide anion attack on the lipoprotein HDL
Napolitano, G., Fasciolo, G., Tomajoli, M. T. M., Carlucci, A., Ascione, E., & Alfonso, S. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04563-5 · Cited by 9
Pitavastatin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia
Chapman, M. J., Orsoni, A., Mellett, N. A., Nguyen, A., Robillard, P., Shaw, J. E., Giral, P., Thérond, P., Swertfeger, D. K., Davidson, W. S., et al. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100494 · Cited by 8
Self-citationDergunov, A. D., Nosova, E. V., Rozhkova, A. V., Vinogradina, M. A., Baserova, V. B., Popov, M. A., Limborska, S. A., & Dergunova, L. V. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2911396 · Cited by 8
Lucchesi, D., Popa, S. G., Sancho, V., Giusti, L., Garofolo, M., Daniele, G., Pucci, L., Miccoli, R., Penno, G., & Prato, S. D. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0720-1 · Cited by 8
Metabolismus und Funktion der Lipoproteine hoher Dichte (HDL)
Jomard, A., & Osto, E. (2019) · Praxis · doi:10.1024/1661-8157/a003241 · Cited by 8
Linking myeloperoxidase with subclinical atherosclerosis in adults with metabolic syndrome
Iana, A., & Sîrbu, E. (2020) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01602-y · Cited by 8
Harun, N. H., Froemming, G. R. A., Ismail, A. M., Nawawi, H. M., Mokhtar, S. S., & Muid, S. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314616 · Cited by 8
The role of atherogenic lipoproteins in diabetes: Molecular aspects and clinical significance
Banerjee, Y., Patti, A. M., Giglio, R. V., Ciaccio, M., Vichithran, S., Faisal, S., Stoian, A. P., Rizvi, A. A., & Rizzo, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108517 · Cited by 8
Messas, N., Dubé, M., & Tardif, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0679-5 · Cited by 8
Sun, L., Zhang, S., Chen, M., Elena, K., & Qiao, H. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.204926 · Cited by 8
Puig, N., Camps‐Renom, P., Hermansson, M., Aguilera‐Simón, A., Marín, R., Bautista, O., Rotllán, N., Sanromán, N. B., Domine, M. C., Öörni, K., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100739 · Cited by 7
Akram, M. A., Khodja, A., Dalibalta, S., & Majdalawieh, A. F. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673348217241119063941 · Cited by 8
Goff, W. L., Bourron, O., Materne, C., Galier, S., Phan, F., Tan, S., Guillas, I., Hartemann, A., Salem, J., Redheuil, A. B., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02624-9 · Cited by 7
Nanomedicine–lipoprotein interactions
Moghimi, S. M., & Simberg, D. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00291-9 · Cited by 7
Asparagine endopeptidase cleaves apolipoprotein A1 and accelerates pathogenesis of atherosclerosis
Wang, M., Li, B., Nie, S., Meng, X., Wang, G., Yang, M., Dang, W., He, K., Sun, T., Xu, P., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci185128 · Cited by 7
Tang, Y., Liu, J., Zhang, J., Zhu, Y., & Zhou, J. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02604-8 · Cited by 7
HDL-C: Helpful, harmful, hopeful, or guilty by association
McLean, P., Mathew, D., Chandrasekhar, S. A., Guynn, N., Razavi, A. C., Quyyumi, A. A., Mehta, A., & Sperling, L. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.017 · Cited by 7
The Association of Upper Body Obesity with Insulin Resistance in the Newfoundland Population
Youssef, S., Nelder, M., & Sun, G. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18115858 · Cited by 7
Zhang, W., Jin, J., Zhang, H., Zhu, Y., Dong, Q., Sun, J., Guo, Y., Dou, K., Xu, R., & Li, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1041555 · Cited by 7
Jin, J., Zhao, X.-J., Zhu, C., Li, M., Wang, J.-X., Fan, Y., Liu, C., Shen, C., & Yang, R.-X. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01533-6 · Cited by 6
Kosugi, T., Eriguchi, M., Yoshida, H., Tamaki, H., Uemura, T., Tasaki, H., Furuyama, R., Fukata, F., Nishimoto, M., Matsui, M., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65107 · Cited by 7
Favari, E., Angelino, D., Cipollari, E., Adorni, M. P., Zimetti, F., Bernini, F., Ronda, N., & Pellegrini, N. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.05.002 · Cited by 7
Zheng, A., Li, H., Feng, Z., & Liu, J. (2021) · Cells · doi:10.3390/cells10112976 · Cited by 7
Apolipoprotein A1 Inhibits Adipogenesis Progression of Human Adipose-Derived Mesenchymal Stem Cells
Su, X., Wang, B., Lai, M., Peng, H., Song, J., Huang, H., Chen, X., & Cheng, Y. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220607085908 · Cited by 7
HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS
Cordero, A., Muñoz‐García, N., Padró, T., Vilahur, G., Bertomeu‐González, V., Escribano, D., Flores, E., Zuazola, P., & Badimón, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065391 · Cited by 7
HDL functionality is dependent on hepatocyte stress defense factors Nrf1 and Nrf2
Trites, M. J., Stebbings, B. M., Aoki, H., Phanse, S., Akl, M. G., Li, L., Babu, M., & Widenmaier, S. B. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1212785 · Cited by 7
Shen, T., Li, Y., Liu, T., Lian, Y., & Kong, L. (2024) · Biomedical Reports · doi:10.3892/br.2024.1729 · Cited by 8
Prediction of the risk of mortality using risk score in patients with coronary heart disease
Chen, Q., Ding, D., Zhang, Y., Yang, Y., Li, Q., Chen, X., Hu, G., & Ling, W. (2016) · Oncotarget · doi:10.18632/oncotarget.13166 · Cited by 7
ABC-Transporter Mediated Sterol Export from Cells Using Radiolabeled Sterols
Yang, A., & Gelissen, I. C. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6875-6_20 · Cited by 7
Soupène, E., Larkin, S. K., & Kuypers, F. A. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217706966 · Cited by 7
Evolutionary and structural constraints influencing apolipoprotein A‐I amyloid behavior
Gisonno, R. A., Masson, T., Ramella, N. A., Barrera, E., Romanowski, V., & Tricerri, M. A. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26217 · Cited by 7
Ichikawa, K., Miyoshi, T., Kotani, K., Osawa, K., Nakashima, M., Nishihara, T., & Ito, H. (2022) · Journal of Cardiology · doi:10.1016/j.jjcc.2022.06.015 · Cited by 7
High‐efficient bacterial production of human ApoA‐I amyloidogenic variants
Giudice, R. D., & Lagerstedt, J. O. (2018) · Protein Science · doi:10.1002/pro.3522 · Cited by 7
Lee, W., Lim, Y. G., Song, Y. J., & Park, K. (2024) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-024-00101-w · Cited by 6
Differences in HDL-related coronary heart disease risk between individuals with and without diabetes
Chen, J., Lu, Q., Geng, T., Wang, Y., Wang, Y., Li, R., Xia, P., Guo, K., Yang, K., Tong, W.-W., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.118553 · Cited by 6
Li, S., Fu, Z., & Zhang, W. (2025) · BMC Public Health · doi:10.1186/s12889-025-22251-z · Cited by 6
Playford, M. P., Neufeld, E. B., Zubirán, R., & Remaley, A. T. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1608384 · Cited by 6
Lin, F., Lin, Y., Shih, C., Lin, S., Tung, Y., Li, C., Chen, Y., Lin, C.-Y., Tsai, Y.-T., & Huang, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105210 · Cited by 6
Zeng, C., Yan, C., Guo, S., Zhu, H., Chen, Y., & Zhan, X. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.008 · Cited by 6
Carbamylated lipoproteins in diabetes
Denimal, D. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.159 · Cited by 6
Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
Konaklieva, M. I., & Plotkin, B. J. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1338567 · Cited by 8
Quintão, E. C. R. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12626 · Cited by 6
Mastroianno, S., Stolfo, G. D., Seripa, D., Pacilli, M. A., Paroni, G., Coli, C., Urbano, M., d’Arienzo, C., Gravina, C., Potenza, D. R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171055 · Cited by 6
Pro- versus Anti-inflammatory Actions of HDLs in Innate Immunity
Kopecky, C., Michlits, G., Säemann, M. D., & Weichhart, T. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.007 · Cited by 6
Zhu, L., Petrlová, J., Gysbers, P., Hebert, H., Wallin, S., Jegerschöld, C., & Lagerstedt, J. O. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.07.017 · Cited by 6
Diabetic dyslipidemia and microvascular complications of diabetes
Karásek, D., & Vaverková, H. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.003 · Cited by 6
de Albuquerque, C. P., Freitas, F. R., Martinelli, A. E. M., Lima, J. H., Coelho, R. F., Junior, C. V. S., Nahas, W. C., Filho, R. K., & Maranhão, R. C. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01305-8 · Cited by 6
[HDL‐C/apoA‐I]: A multivessel cardiometabolic risk marker in women with T2DM
Hermans, M. P., Valensi, P. E., Ahn, S. A., & Rousseau, M. F. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2950 · Cited by 6
Chen, C., Hsu, Y.-P., Liu, J., Kao, P., Sung, L., Lin, C., Hao, W., Liu, S., & Wu, S. (2016) · Journal of Cancer · doi:10.7150/jca.15779 · Cited by 6
Kunutsor, S. K., Rikhtehgaran, R., Connelly, M. A., SHALAUROVA, I. Y., Bakker, S. J. L., & Dullaart, R. P. F. (2025) · Nutrients · doi:10.3390/nu17111747 · Cited by 5
Li, B., Xu, Y., He, Q., Yin, Q., Wu, M., Zhu, H., & Cao, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1560022 · Cited by 5
Fang, Z., Jiang, Z., Wang, X., Chen, X., & Yang, Y. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05121-9 · Cited by 5
Guo, X., Shen, R., Lu, P., & Ma, L. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12350 · Cited by 5
Cho, K., Bahuguna, A., Lee, Y., Lee, S. H., Domínguez-Horta, M. D. C., & Martínez‐Donato, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105560 · Cited by 7
Davis, T. M. E., Chubb, S. A. P., & Davis, W. A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02447-0 · Cited by 5
Xie, L., Luo, H., Zhao, Y., Hao, Y., Gao, J., Sun, C., & Hu, H. (2025) · Biogerontology · doi:10.1007/s10522-025-10201-6 · Cited by 5
Abnormal epigenetic modification of lysosome and lipid regulating genes in Alzheimer’s disease
Ruan, T., Ling, Y., Wu, C., Niu, Y., Liu, G., Xu, C., Lv, Z., Yuan, Y., Zhou, X., Wang, Q., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251322955 · Cited by 5
Correlation of peripheral olfactomedin 1 with Alzheimer’s disease and cognitive functions
Wei, C., Zhang, G., Fu, X., Zhao, M. L., Zhai, W., Shen, Y., & Sun, L. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03373-9 · Cited by 5
The EGR3 gene modulates CRP and VCAM-1 expression to promote the development of atherosclerosis
Li, J., Zhang, L., Abudukeyimu, Z., Wang, S., Wang, S., Wang, H., Wu, Y., Tuohetiyaer, K., & Li, X. (2025) · Gene · doi:10.1016/j.gene.2025.149630 · Cited by 5
Cholesterol and Radiosensitivity
Rahal, O. M., & Woodward, W. A. (2016) · Current Breast Cancer Reports · doi:10.1007/s12609-016-0202-y · Cited by 5
Ribeiro, F. R. C. D. M., Ribeiro, C. H. M. A., Tavoni, T. M., Sarges, E. D. S., Freitas, F. R., Stolf, N. A. G., Filho, R. K., & Maranhão, R. C. (2021) · Vascular Medicine · doi:10.1177/1358863x211021142 · Cited by 5
Pashinskaya, K. O., Васильевна, С. А., & Dobrodeeva, L. K. (2021) · Russian Clinical Laboratory Diagnostics · doi:10.51620/0869-2084-2021-66-9-539-545 · Cited by 5
Lu, R., Wang, W., Dong, B., Xu, C. Y., Li, B., Sun, Y., Liu, J., & Hong, B. (2022) · Molecules · doi:10.3390/molecules27238134 · Cited by 6
English, C. J., Lohning, A. E., Mayr, H. L., Jones, M., & Reidlinger, D. P. (2022) · BioFactors · doi:10.1002/biof.1928 · Cited by 5
Yu, B., Han, X., Wang, J., Long, W., Zhou, W., Yuan, X., & Zhang, B. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.04.004 · Cited by 5
Chen, X., Xiang, Y.-F., Cai, X., Chen, J., Lin, X., Lin, B., Liang, W.-J., Zhou, G., Guo, Y., & Lin, K. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.131773 · Cited by 5
The Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy
Wańczura, P. M., Aebisher, D., Iwański, M. A., Myśliwiec, A., Dynarowicz, K., & Bartusik‐Aebisher, D. (2024) · Biomedicines · doi:10.3390/biomedicines12050961 · Cited by 5
Modified risk associations of lipoproteins and apolipoproteins by chronic low-grade inflammation
Onat, A., Kaya, A., & Ademoğlu, E. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1417839 · Cited by 5
An update on trials of novel lipid-lowering drugs
Wierzbicki, A. S., Reynolds, T., & Viljoen, A. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000518 · Cited by 5
Inoue, Y., Okamoto, T., Honda, T., Nukui, Y., Akashi, T., Takemura, T., Tozuka, M., & Miyazaki, Y. (2020) · Immunity Inflammation and Disease · doi:10.1002/iid3.355 · Cited by 5
Wu, H., Wang, C., Tuerhongjiang, G., Qiao, X., Hua, Y., She, J., & Yuan, Z. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001803 · Cited by 5
Sun, L., Guo, M., Xu, C., Qiao, X., Hua, Y., Tuerhongjiang, G., Lou, B., Li, R., Bai, X., Zhou, J., et al. (2021) · Disease Markers · doi:10.1155/2021/6689056 · Cited by 5
Effects of ABCG1 knockout on proteomic composition of HDL in mice on a chow diet and a high‐fat diet
Wu, Y., Chen, L., Xie, Z., Wang, C., Zhang, J., & Yan, X. (2022) · PROTEOMICS · doi:10.1002/pmic.202100028 · Cited by 5
Cervellati, C., Trentini, A., Rosta, V., Zuliani, G., Sega, F. V. D., Fortini, F., Rizzo, P., Cimaglia, P., & Campo, G. C. (2023) · Current Vascular Pharmacology · doi:10.2174/1570161121666230221142131 · Cited by 5
Metadata
- Authors
- Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- MedStar Washington Hospital Center (US)
- University of California, Los Angeles (US)
- UNSW Sydney (AU)
- Inserm (FR)
- University of Washington (US)
- Columbia University (US)
- University of Kentucky (US)
- Corresponding author
- Rosenson, Robert S.
- Venue
- Nature Reviews Cardiology
- Published
- 2015-09-01
- Volume
- 13
- Issue
- 1
- Pages
- 48-60
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- PMC
- PMC6245940
- OpenAlex
- W2175680864
- Cited by
- 822
- References
- 131
- Citations by year
- 2026: 89 · 2025: 89 · 2024: 66 · 2023: 79 · 2022: 86 · 2021: 79 · 2020: 79 · 2019: 62 · 2018: 69 · 2017: 61 · 2016: 56 · 2015: 5
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK108209, P30DK017047)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- HDL dysfunction, atherosclerosis, apolipoprotein A-I, reverse cholesterol transport, ABCA1, ABCG1, myeloperoxidase, nitrosylation, oxidative modification, inflammation, endothelial function, coronary artery disease, atherogenesis, anti-inflammatory activity
- MeSH terms
- Humans, Lipoproteins, HDL, Macrophages, Smoking, Apolipoprotein A-I, ATP-Binding Cassette Transporters, Diabetes Complications, Atherosclerosis, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
